Please use this identifier to cite or link to this item: https://doi.org/10.1159/000348325
Title: Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: The emerging role for radioembolization using yttrium-90
Authors: Lau, W.-Y.
Sangro, B.
Chen, P.-J.
Cheng, S.-Q.
Chow, P. 
Lee, R.-C.
Leung, T.
Han, K.-H.
Poon, R.T.P.
Keywords: Hepatocellular carcinoma
Portal vein tumor thrombosis
Transarterial chemoembolization
Transarterial radioembolization
Yttrium-90
Issue Date: May-2013
Citation: Lau, W.-Y., Sangro, B., Chen, P.-J., Cheng, S.-Q., Chow, P., Lee, R.-C., Leung, T., Han, K.-H., Poon, R.T.P. (2013-05). Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: The emerging role for radioembolization using yttrium-90. Oncology (Switzerland) 84 (5) : 311-318. ScholarBank@NUS Repository. https://doi.org/10.1159/000348325
Abstract: Background/Purpose: Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) have an extremely poor prognosis and relatively few treatment options. Method: During a consensus meeting, experts met to examine the published data for HCC treatment strategies in patients with PVTT. Results: Many treatment guidelines consider the presence of PVTT a contraindication to partial hepatectomy or liver transplantation. Transarterial chemoembolization (TACE) is associated with an increased risk of ischemic necrosis of liver and of treatment-related death in patients with PVTT, and is, therefore, limited to a select group of patients with good hepatic function and adequate collateral circulation around the occluded portal vein. Systemic sorafenib results in survival benefit in patients regardless of the presence of PVTT. However, side effects are common, and there are no effects on time-to-symptom progression or quality of life. Transarterial radioembolization (TARE) with yttrium-90 microspheres is emerging as a valuable strategy. A wider range of patients with PVTT are suitable for this procedure compared to TACE. TARE is as effective as TACE in HCC and has quality-of-life advantages. Conclusion: In patients with HCC with PVTT, medical evidence suggests that TARE is a good choice of treatment. Copyright © 2013 S. Karger AG, Basel.
Source Title: Oncology (Switzerland)
URI: http://scholarbank.nus.edu.sg/handle/10635/110458
ISSN: 00302414
DOI: 10.1159/000348325
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

103
checked on Oct 13, 2021

WEB OF SCIENCETM
Citations

101
checked on Oct 13, 2021

Page view(s)

94
checked on Oct 14, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.